A Phase 4 interventional study of Ezetimibe and Atorvastatin in Primary Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-23.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 58th largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2009, is one of 31 in phase 4, and was the 59th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 64th largest by enrollment of the 81 interventional ones that give a count, is one of 3 that started in 2009, is one of 19 in phase 4, and was the 71st registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of atorvastatin 10 mg and ezetimibe 10 mg coadministration in Japanese participants with hypercholesterolemia whose low-density lipoprotein (LDL)-cholesterol levels have not reached the lipid management target value with atorvastatin 10 mg alone, versus increasing the dose of atorvastatin to 20 mg or changing to rosuvastatin 2.5 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
Drug: Ezetimibe · Drug: Atorvastatin
Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
Drug: Atorvastatin
Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
Drug: Rosuvastatin
1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
Also known as: SCH 058235
1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values
LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).
Time frame: End of Week 4 to Week 16 or discontinuation
Percent Change in LDL-C
LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).
Time frame: End of washout period to Week 16 or discontinuation
Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values
LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation). Target values: For participants with history of coronary artery disease: \<100 mg/dL; for participants with at least 3 cardiovascular (CV) risk factors: \<120 mg/dL; for participants with 1-2 CV risk factors: \<140 mg/dL; for participants with no CV risk factors: \<160 mg/dL.
Time frame: Week 16 or discontinuation
Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)
Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.
Time frame: End of Week 4 to Week 16 or discontinuation
Percent Change in Total Lipids and Hs-CRP
Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).
Time frame: End of washout to Week 16 or discontinuation
| Milestone | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| Started | 47 | 46 | 32 |
| Completed | 43 | 45 | 32 |
| Not completed | 4 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 0 |
LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).
| Percent change | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values | -25.8 (-29.2 to -22.4) | -15.1 (-18.6 to -11.7) | 0.8 (-3.3 to 4.9) |
LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).
| Percent change | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| Percent Change in LDL-C | -49.6 (-52.9 to -46.4) | -41.1 (-44.4 to -37.9) | -30.5 (-34.4 to -26.6) |
LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation). Target values: For participants with history of coronary artery disease: \<100 mg/dL; for participants with at least 3 cardiovascular (CV) risk factors: \<120 mg/dL; for participants with 1-2 CV risk factors: \<140 mg/dL; for participants with no CV risk factors: \<160 mg/dL.
| Participants | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values | 37 | 19 | 1 |
Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.
| Percent change | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| Total Cholesterol | -18.0 (-20.7 to -15.2) | -10.3 (-13.1 to -7.4) | 1.9 (-1.7 to 5.5) |
| Triglycerides | -0.8 (-14.4 to 12.8) | 0.2 (-10.9 to 11.4) | 14.7 (2.3 to 27.0) |
| High-Density Lipoprotein Cholesterol (HDL-C) | 4.5 (0.9 to 8.2) | 0.5 (-2.6 to 3.5) | 2.5 (-1.4 to 6.4) |
| Non-HDL-C | -25.0 (-28.5 to -21.5) | -13.7 (-17.0 to -10.3) | 2.0 (-2.6 to 6.5) |
| High Sensitivity C-Reactive Protein (Hs-CRP) | 49.0 (-43.2 to 141.3) | 9.9 (-24.1 to 43.9) | 25.7 (-4.8 to 56.1) |
Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).
| Percent change | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| Total Cholesterol | -39.9 (-42.1 to -37.7) | -32.8 (-35.8 to -29.7) | -24.4 (-27.9 to -21.0) |
| Triglycerides | -25.3 (-36.0 to -14.6) | -18.8 (-29.8 to -7.8) | -12.0 (-21.3 to -2.7) |
| High-Density Lipoprotein Cholesterol (HDL-C) | 10.3 (6.1 to 14.5) | 7.4 (3.7 to 11.0) | 9.9 (3.6 to 16.2) |
| Non-HDL-C | -50.1 (-52.7 to -47.6) | -41.4 (-44.8 to -37.9) | -31.3 (-35.4 to -27.1) |
| High Sensitivity C-reactive Protein (Hs-CRP) | 73.0 (-84.4 to 230.4) | -2.9 (-36.3 to 30.4) | -13.6 (-39.7 to 12.6) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe + Atorvastatin | — | 4/47 (8.5%) | 13/47 (27.7%) |
| Atorvastatin | — | 1/46 (2.2%) | 5/46 (10.9%) |
| Rosuvastatin | — | 0/32 (0%) | 9/32 (28.1%) |
| Event | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/47 | 1/46 | 0/32 |
| Chest discomfortGeneral disorders | 1/47 | 0/46 | 0/32 |
| Heat illnessInjury, poisoning and procedural complications | 1/47 | 0/46 | 0/32 |
| Carcinoid tumour of the gastrointestinal tractNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/47 | 0/46 | 0/32 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/47 | 0/46 | 0/32 |
| Event | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/47 | 5/46 | 3/32 |
| HeadacheNervous system disorders | 1/47 | 0/46 | 3/32 |
| HypertensionVascular disorders | 2/47 | 0/46 | 3/32 |
| Blood creatine phosphokinase increasedInvestigations | 3/47 | 0/46 | 0/32 |
| DizzinessNervous system disorders | 0/47 | 0/46 | 2/32 |
| Age, Continuous(years) | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin | Total |
|---|---|---|---|---|
| Mean | 62.7 ± 11.4 | 59.3 ± 11.8 | 61.1 ± 12.0 | 61.0 ± 11.7 |
| Sex: Female, Male(Participants) | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin | Total |
|---|---|---|---|---|
| Female | 25 | 22 | 17 | 64 |
| Male | 22 | 24 | 15 | 61 |
| Region of Enrollment(participants) | Ezetimibe + Atorvastatin | Atorvastatin | Rosuvastatin | Total |
|---|---|---|---|---|
| Japan | 47 | 46 | 32 | 125 |
No study locations are listed for this record.
Plan to share: No
Ran from Feb 2009 to primary completion in May 2010, 15 months.
Results were first posted in Aug 2011, 1 year 3 months after primary completion.
Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Atorvastatin